Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
Halpern AB, Othus M, Huebner EM, Scott BL, Hendrie PC, Percival MM, Becker PS, Smith HA, Oehler VG, Orozco JJ, Cassaday RD, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Estey EH, Walter RB. Halpern AB, et al. Among authors: buckley sa. Haematologica. 2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8. Haematologica. 2019. PMID: 30409798 Free PMC article. Clinical Trial. No abstract available.
Height as an explanatory factor for sex differences in human cancer.
Walter RB, Brasky TM, Buckley SA, Potter JD, White E. Walter RB, et al. Among authors: buckley sa. J Natl Cancer Inst. 2013 Jun 19;105(12):860-8. doi: 10.1093/jnci/djt102. Epub 2013 May 24. J Natl Cancer Inst. 2013. PMID: 23708052 Free PMC article.
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, Fang M, Gyurkocza B, Delaney C, Radich JP, Estey EH, Appelbaum FR. Walter RB, et al. Among authors: buckley sa. Blood. 2013 Sep 5;122(10):1813-21. doi: 10.1182/blood-2013-06-506725. Epub 2013 Jul 11. Blood. 2013. PMID: 23847197 Free PMC article.
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.
Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA, Sorror ML, Wood BL, Storb R, Appelbaum FR, Sandmaier BM. Walter RB, et al. Among authors: buckley sa. Leukemia. 2015 Jan;29(1):137-44. doi: 10.1038/leu.2014.173. Epub 2014 Jun 3. Leukemia. 2015. PMID: 24888275 Free PMC article.
Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.
Walter RB, Sandmaier BM, Storer BE, Godwin CD, Buckley SA, Pagel JM, Sorror ML, Deeg HJ, Storb R, Appelbaum FR. Walter RB, et al. Among authors: buckley sa. Biol Blood Marrow Transplant. 2015 Feb;21(2):373-8. doi: 10.1016/j.bbmt.2014.09.022. Epub 2014 Sep 30. Biol Blood Marrow Transplant. 2015. PMID: 25278455 Free PMC article.
85 results